Given widely available evidence that Lp(a) is an independent risk factor for ASCVD, drugs which can specifically lower Lp(a) in patients with an elevated baseline of Lp(a) and which also result in better CV outcomes are the need of the hour. This evidence concerns the gene LPA and atherosclerosis.